vs
Side-by-side financial comparison of BRIGHT HORIZONS FAMILY SOLUTIONS INC. (BFAM) and Organon & Co. (OGN). Click either name above to swap in a different company.
Organon & Co. is the larger business by last-quarter revenue ($1.5B vs $733.7M, roughly 2.0× BRIGHT HORIZONS FAMILY SOLUTIONS INC.). On growth, BRIGHT HORIZONS FAMILY SOLUTIONS INC. posted the faster year-over-year revenue change (8.8% vs -3.5%). Over the past eight quarters, BRIGHT HORIZONS FAMILY SOLUTIONS INC.'s revenue compounded faster (8.5% CAGR vs -4.7%).
Bright Horizons Family Solutions Inc. is a United States–based child-care provider and is the largest provider of employer-sponsored child care. It also provides back-up child care and elder care, tuition program management, education advising, and student loan repayment programs. It is headquartered in Newton, Massachusetts.
Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, hormone replacement therapy (HRT), and anesthesia. Organon produces all its products outside of the United States but receives a third of its revenue from the United States.
BFAM vs OGN — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $733.7M | $1.5B |
| Net Profit | — | $146.0M |
| Gross Margin | 19.3% | 53.6% |
| Operating Margin | 6.2% | — |
| Net Margin | — | 10.0% |
| Revenue YoY | 8.8% | -3.5% |
| Net Profit YoY | — | 67.8% |
| EPS (diluted) | $0.38 | $0.55 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $1.5B | ||
| Q4 25 | $733.7M | $1.5B | ||
| Q3 25 | $802.8M | $1.6B | ||
| Q2 25 | $731.6M | $1.6B | ||
| Q1 25 | $665.5M | $1.5B | ||
| Q4 24 | $674.1M | $1.6B | ||
| Q3 24 | $719.1M | $1.6B | ||
| Q2 24 | $670.1M | $1.6B |
| Q1 26 | — | $146.0M | ||
| Q4 25 | — | $-205.0M | ||
| Q3 25 | $78.6M | $160.0M | ||
| Q2 25 | $54.8M | $145.0M | ||
| Q1 25 | $38.0M | $87.0M | ||
| Q4 24 | — | $109.0M | ||
| Q3 24 | $54.9M | $359.0M | ||
| Q2 24 | $39.2M | $195.0M |
| Q1 26 | — | 53.6% | ||
| Q4 25 | 19.3% | 49.2% | ||
| Q3 25 | 27.0% | 53.5% | ||
| Q2 25 | 25.0% | 54.8% | ||
| Q1 25 | 23.4% | 55.6% | ||
| Q4 24 | 20.8% | 56.3% | ||
| Q3 24 | 25.2% | 58.3% | ||
| Q2 24 | 24.2% | 58.4% |
| Q1 26 | — | — | ||
| Q4 25 | 6.2% | -9.8% | ||
| Q3 25 | 15.1% | 15.2% | ||
| Q2 25 | 11.8% | 14.4% | ||
| Q1 25 | 9.4% | 6.7% | ||
| Q4 24 | 7.2% | 8.1% | ||
| Q3 24 | 12.4% | 13.1% | ||
| Q2 24 | 10.3% | 14.6% |
| Q1 26 | — | 10.0% | ||
| Q4 25 | — | -13.6% | ||
| Q3 25 | 9.8% | 10.0% | ||
| Q2 25 | 7.5% | 9.1% | ||
| Q1 25 | 5.7% | 5.8% | ||
| Q4 24 | — | 6.8% | ||
| Q3 24 | 7.6% | 22.7% | ||
| Q2 24 | 5.8% | 12.1% |
| Q1 26 | — | $0.55 | ||
| Q4 25 | $0.38 | $-0.78 | ||
| Q3 25 | $1.37 | $0.61 | ||
| Q2 25 | $0.95 | $0.56 | ||
| Q1 25 | $0.66 | $0.33 | ||
| Q4 24 | $0.50 | $0.42 | ||
| Q3 24 | $0.94 | $1.38 | ||
| Q2 24 | $0.67 | $0.75 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $140.1M | — |
| Total DebtLower is stronger | $747.6M | — |
| Stockholders' EquityBook value | $1.3B | — |
| Total Assets | $3.9B | — |
| Debt / EquityLower = less leverage | 0.56× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $140.1M | $574.0M | ||
| Q3 25 | $116.6M | $672.0M | ||
| Q2 25 | $179.2M | $599.0M | ||
| Q1 25 | $112.0M | $547.0M | ||
| Q4 24 | $110.3M | $675.0M | ||
| Q3 24 | $109.9M | $763.0M | ||
| Q2 24 | $140.2M | $704.0M |
| Q1 26 | — | — | ||
| Q4 25 | $747.6M | $8.6B | ||
| Q3 25 | $747.5M | $8.8B | ||
| Q2 25 | $797.0M | $8.9B | ||
| Q1 25 | $872.7M | $9.0B | ||
| Q4 24 | $918.4M | $8.9B | ||
| Q3 24 | $925.7M | $8.7B | ||
| Q2 24 | $931.9M | $8.7B |
| Q1 26 | — | — | ||
| Q4 25 | $1.3B | $752.0M | ||
| Q3 25 | $1.4B | $906.0M | ||
| Q2 25 | $1.4B | $733.0M | ||
| Q1 25 | $1.3B | $542.0M | ||
| Q4 24 | $1.3B | $472.0M | ||
| Q3 24 | $1.4B | $493.0M | ||
| Q2 24 | $1.3B | $144.0M |
| Q1 26 | — | — | ||
| Q4 25 | $3.9B | $12.9B | ||
| Q3 25 | $3.9B | $13.6B | ||
| Q2 25 | $3.9B | $13.5B | ||
| Q1 25 | $3.8B | $13.2B | ||
| Q4 24 | $3.9B | $13.1B | ||
| Q3 24 | $3.9B | $12.8B | ||
| Q2 24 | $3.8B | $12.2B |
| Q1 26 | — | — | ||
| Q4 25 | 0.56× | 11.49× | ||
| Q3 25 | 0.52× | 9.74× | ||
| Q2 25 | 0.57× | 12.14× | ||
| Q1 25 | 0.66× | 16.52× | ||
| Q4 24 | 0.72× | 18.81× | ||
| Q3 24 | 0.66× | 17.75× | ||
| Q2 24 | 0.73× | 60.11× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $350.7M | — |
| Free Cash FlowOCF − Capex | $258.5M | — |
| FCF MarginFCF / Revenue | 35.2% | — |
| Capex IntensityCapex / Revenue | 12.6% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $402.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $350.7M | $141.0M | ||
| Q3 25 | $-17.6M | $264.0M | ||
| Q2 25 | $134.2M | $220.0M | ||
| Q1 25 | $86.2M | $75.0M | ||
| Q4 24 | $337.5M | $390.0M | ||
| Q3 24 | $-8.9M | $141.0M | ||
| Q2 24 | $109.4M | $332.0M |
| Q1 26 | — | — | ||
| Q4 25 | $258.5M | $96.0M | ||
| Q3 25 | $-42.4M | $218.0M | ||
| Q2 25 | $115.4M | $181.0M | ||
| Q1 25 | $70.9M | $43.0M | ||
| Q4 24 | $240.2M | $335.0M | ||
| Q3 24 | $-32.2M | $99.0M | ||
| Q2 24 | $86.8M | $300.0M |
| Q1 26 | — | — | ||
| Q4 25 | 35.2% | 6.4% | ||
| Q3 25 | -5.3% | 13.6% | ||
| Q2 25 | 15.8% | 11.4% | ||
| Q1 25 | 10.7% | 2.8% | ||
| Q4 24 | 35.6% | 21.0% | ||
| Q3 24 | -4.5% | 6.3% | ||
| Q2 24 | 13.0% | 18.7% |
| Q1 26 | — | — | ||
| Q4 25 | 12.6% | 3.0% | ||
| Q3 25 | 3.1% | 2.9% | ||
| Q2 25 | 2.6% | 2.4% | ||
| Q1 25 | 2.3% | 2.1% | ||
| Q4 24 | 14.4% | 3.5% | ||
| Q3 24 | 3.2% | 2.7% | ||
| Q2 24 | 3.4% | 2.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | -0.22× | 1.65× | ||
| Q2 25 | 2.45× | 1.52× | ||
| Q1 25 | 2.26× | 0.86× | ||
| Q4 24 | — | 3.58× | ||
| Q3 24 | -0.16× | 0.39× | ||
| Q2 24 | 2.79× | 1.70× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BFAM
Segment breakdown not available.
OGN
| Established Brands | $880.0M | 60% |
| Women’s Health | $389.0M | 27% |
| Biosimilars | $173.0M | 12% |
